<DOC>
	<DOCNO>NCT01310816</DOCNO>
	<brief_summary>IPI-926 inhibitor hedgehog pathway . IPI-926 may improve therapeutic outcome patient Chondrosarcoma .</brief_summary>
	<brief_title>A Safety Efficacy Study Patients With Metastatic Locally Advanced ( Unresectable ) Chondrosarcoma</brief_title>
	<detailed_description>Study IPI-926-04 Phase 2 , double-blind , placebo-controlled , multicenter , trial evaluate safety efficacy IPI-926 patient metastatic locally advanced ( unresectable ) chondrosarcoma . The study include optional cross-over open-label IPI-926 patient randomly assign placebo experience document disease progression .</detailed_description>
	<mesh_term>Chondrosarcoma</mesh_term>
	<criteria>At least 18 year age time sign informed consent . Pathologically diagnosed conventional chondrosarcoma . Patients must tumor sample ( ) available provide tumor sample new biopsy Metastasis least 1 location locally advanced disease deem unresectable surgeon At least 1 radiologically measurable target lesion per RECIST 1.1 . Patients must document radiographic progression disease within 6month period prior screen . ( MRI CT Scan ) Eastern Cooperative Oncology Group ( ECOG ) performance status : 0 1 . Life expectancy least 3 month All woman childbearing potential ( WCBP ) , sexually active male patient , partner patient must agree use adequate method birth control throughout study 30 day last dose study drug . Ability adhere study visit schedule protocol requirement . Voluntarily sign informed consent form . Other invasive malignancy diagnose within last 5 year , except nonmelanoma skin cancer localize cured prostate cervical cancer . Systemic anticancer therapy within 21 day prior first dose study drug , radiotherapy within 14 day prior first dose study drug . Prior treatment Hedgehog pathway inhibitor Medically significant surgical procedure significant traumatic injury within 28 day Day 1 . Inadequate hematologic function define : Hemoglobin &lt; 8.0 g/dL ( 80 g/L ) ( may increase level transfusion long evidence active bleeding ) . Inadequate hepatic function define : Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN ) . Total bilirubin &gt; 1.5 x ULN ( exception patient Gilbert 's disease ) . Cirrhotic liver disease , ongoing alcohol abuse , know chronic active acute hepatitis . Inadequate renal function define serum creatinine &gt; 1.5 x ULN Patients history stroke , unstable angina , myocardial infarction , ventricular arrhythmia require medication mechanical control within last 6 month . Presence active infection systemic use antibiotic within 72 hour treatment . Significant comorbid condition disease , judgment Investigator , would place patient undue risk interfere study . Examples include , limited sepsis recent significant traumatic injury . Known human immunodeficiency virus ( HIV ) positivity . Known hypersensitivity IPI926 , excipients IPI926 placebo capsule . Pregnant lactating woman . Current administration medication food know moderate strong inhibitor CYP3A4 activity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>malignant neoplasm bone</keyword>
	<keyword>bone sarcoma</keyword>
</DOC>